May 2003
Volume 44, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2003
Anti-TNFalpha Therapy in Patients with Posterior Segment Intraocular Inflammation Refractory to Conventional Immunosuppressants
Author Affiliations & Notes
  • K.H. Greiner
    Department of Ophthalmology, University of Aberdeen, Aberdeen, United Kingdom
  • C. Murphy
    Division of Ophthalmology, University of Bristol, Bristol, United Kingdom
  • F. Willermain
    Division of Ophthalmology, University of Bristol, Bristol, United Kingdom
  • L. Duncan
    Division of Ophthalmology, University of Bristol, Bristol, United Kingdom
  • L. Kuffova
    Division of Ophthalmology, University of Bristol, Bristol, United Kingdom
  • J. Plskova
    Division of Ophthalmology, University of Bristol, Bristol, United Kingdom
  • I. Tomida
    Division of Ophthalmology, University of Bristol, Bristol, United Kingdom
  • G. Hale
    Therapeutic Antibody Center, Oxford, United Kingdom
  • J.V. Forrester
    Therapeutic Antibody Center, Oxford, United Kingdom
  • A. Dick
    Therapeutic Antibody Center, Oxford, United Kingdom
  • Footnotes
    Commercial Relationships  K.H. Greiner, None; C. Murphy, None; F. Willermain, None; L. Duncan, None; L. Kuffova, None; J. Plskova, None; I. Tomida, None; G. Hale, None; J.V. Forrester, None; A. Dick, None.
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 2010. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      K.H. Greiner, C. Murphy, F. Willermain, L. Duncan, L. Kuffova, J. Plskova, I. Tomida, G. Hale, J.V. Forrester, A. Dick; Anti-TNFalpha Therapy in Patients with Posterior Segment Intraocular Inflammation Refractory to Conventional Immunosuppressants . Invest. Ophthalmol. Vis. Sci. 2003;44(13):2010.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: Clinically, non-infectious posterior segment intraocular inflammation (PSII) represents Th1 cell mediated disorders where experimental correlates show that the immunomodulatory effect of neutralising TNF alpha activity profoundly suppresses target organ damage. This study investigated the efficacy and possible immunomodulatory effects of anti-TNFalpha therapy in PSII. Methods: Sixteen patients with PSII refractory to previous immunosuppressive therapy were enrolled. A single i.v. infusion of a recombinant protein (TNFr-Ig) generated by fusing the p55 TNF receptor with human IgG1 was administered. During 20 treatment periods clinical outcome measures (visual acuity, BIO score, occurrence and extent of macular oedema) were monitored at 0, 2, 4, 8 and 12 weeks. Reduction of other immunosuppressive agents was recorded as a secondary outcome measure. Flow cytometric assessment of CD69 and CD62L expression on CD4+ T cells was performed to determine surrogate markers of treatment effectivity. Expression levels of CD69 and CD62L were compared to a population of normal controls. Results: All clinical outcome measures (visual acuity, BIO score, macular oedema) significantly improved 2 and 4 weeks after treatment with TNFr-Ig (p<0.01). Recurrences of PSII typically occurred after 8-12 weeks. A repeat infusion led to clinical improvement in these patients. No serious side effects of TNFr-Ig were observed. Treatment reduced extent of CD69 expression (p<0.05) and level of CD62L expression (MFI) after 2 weeks as compared to pretreatment (p<0.05) and normal (p<0.01) controls. Conclusions: Neutralising TNF alpha activity in PSII results in a marked and rapid resolution of inflammation and recovery of visual function, which lasts for 4-6 weeks, and is accompanied by down-regulation of peripheral CD4+ T cell activation.

Keywords: uveitis-clinical/animal model • inflammation • immunomodulation/immunoregulation 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×